Recovery Report: Momentive Specialty Chemicals Inc.'s Recovery Rating Profile Nov 11

  • ID: 2027233
  • November 2011
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services is updating its recovery analysis on Momentive Specialty Chemicals Inc.'s (MSC) rated debt, as part of our ongoing ratings surveillance process. Our simulated default scenario contemplates a default in 2013, due to weaker demand for MSC's products amid recessionary conditions. This would compress the company's operating margins to single digits from recently improved levels, resulting in severely constrained liquidity and covenant compliance challenges. Our estimated distressed emergence EBITDA of $294 million assumes that the company would emerge at a time when cyclical demand gains some momentum from its trough levels. As a result, we estimate gross recovery valuation for creditors to be $1.6 billion. On Oct. 1, 2010, the parent holding companies of MSC and...

Companies mentioned in this report are:
- Hexion Inc.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Hexion Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.